CAR T cell Therapy Market

CAR T cell Therapy Market Size (2022 to 2027)

The global CAR T cell market is growing continuously due to innovation and development in this therapy. As a result, the Global CAR T cell therapy market size will exhibit a remarkable CAGR of 52% from 2022 to 2027.

To provide realistic strategies for informed CAR-T care decision-making in patients with hematological malignancies in the face of the COVID-19 pandemic. CAR-T cells in the fourth and next generation have been engineered to improve their capacity to destroy tumors, prolong their survival in vivo, invade solid tumor tissues, and modulate the immune microenvironment. The features of various types of disease should be considered as these methods evolve as therapies for hematological malignancies. The issue with B cell Everything is that it requires methods to increase initial effectiveness and required changes in CAR-T cell survival and assisting patients in regaining an immune response to the tumor. Furthermore, since a cure for hematological malignancies can never be obtained by depending on a single drug, combination therapies and disease-tracking methods should be developed concurrently. Finally, technical advancements and the growth of universal CAR-T cell and CAR NK cell therapy could lower the cost of CAR-T cell therapy, allowing it to be accepted by most patients and payors.

According to the National Cancer Institute, Chimeric Antigen Receptor (CAR) T cell therapy is one type of cancer treatment that helps change patients' T cells so they will attack cancer cells. Firstly, the CAR T cell grew in the laboratory and was given to patients by infusion. CAR T cells' distinctive characteristic is to bind to an antigen on the cancer cells and kill them. CAR T cell therapy treatment is mainly used in blood cancer. Recently, CAR T cell therapy has been preferred over radiation and chemotherapy.

CAR T cells become activated when targeted over antigen and bind to it to destroy the specific cells. The transfer of T cells is an anti-cancer therapeutic process that focuses virtually on any tumor-associated antigen. These only apply to blood cancers in earlier days, but later on, with the advanced technologies, these are moved to various types of cancers.

MARKET DRIVERS:

Y-O-Y growth in the prevalence of Cancer and a growing number of patients failing to respond to alternative treatments are majorly increasing the global CAR T cell therapy market growth.

Suppose the number of adults and children diagnosed with cancer rises. In that case, there will be a greater need for an efficient and dependable clinical care strategy to improve patient quality of life. The global CAR-T cell therapy market is expected to expand due to these developments. Furthermore, the industry is being driven by rising government measures to enhance healthcare facilities and promote cancer-cell therapy research.

Awareness regarding health and wellness, modification in various disorders, and government support worldwide are vital factors that ramp up the CAR T cell therapy market. Although the t- cell treatment systems are available, all oncology specialty hospitals provide immediate therapy to patients in clinics and ambulatory centers, helping reach the highest CAR T-cell market globally. T-cell therapy has the fastest growth rate in lymphoma treatment because it has not preferred another medication. The government's increased support in introducing reimbursement schemes in favor of the poor people is also escalating the market demand. Rapid industry development and aid across all regions is the new opportunity for the CAR T cell therapy market.

Furthermore, implementing advanced technologies and innovative treatment procedures with fewer side effects is expected to surge the market's growth rate. In addition, the rise in investments in research institutes related to cell therapy is another considerable factor supporting market growth.

MARKET RESTRAINTS:

Lack of awareness in the rural areas towards the therapeutic process for cancer disease slightly restrains the CAR T cell therapy market's demand. In addition, the cost of this therapy is a bit expensive, which cannot be affordable by ordinary people, is also hindering the market's demand. Furthermore, an increasing adverse drug reaction concern with cell therapy in Cytokine syndrome problems and the neurological problem is expected to hamper the CAR T cell therapy market growth.

Aside from that, difficulties associated with the CAR-T cell manufacturing process, logistical challenges faced by healthcare organizations, and costly treatment and poorly developed reimbursement policies are impeding the industry's growth. According to the American Cancer society, some people have experienced severe side effects due to this procedure, especially as the CAR T cells multiply in the body to combat Cancer. CAR T cells produce many chemicals called cytokines, which are released into the bloodstream as they multiply. In the days following treatment, this release's serious side effects can include very high fevers and dangerously low blood pressure. The condition is known as cytokine release syndrome (CRS). Neurotoxicity, or changes in the brain that cause swelling, depression, seizures, or extreme headaches, is another dangerous side effect. Another issue is that CAR T cells will destroy some healthy B cells that help combat infection, putting the patient at risk of infection.

Impact of COVID-19 on the CAR-T cell therapy Market:

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-caused coronavirus disease 2019 (COVID-19) pandemic is increasingly spreading worldwide. The COVID-19 pandemic is impacting the availability of critical routine healthcare facilities and procedures, such as CAR-T therapy, a life-saving alternative for patients with relapsed/refractory (R/R) hematologic malignancies. In addition, there is an immediate need to produce and use CAR T-cells due to the rapid disease development of hematological malignancies. During the COVID-19 pandemic, however, CAR-T treatment has become burdensome. As a result, several medical and technological factors must now be considered before, during, and after CAR-T therapy.

Amid the current COVID-19 pandemic, this review aims to include brief recommendations for sound decision-making strategies in assessing and selecting CAR T-cell treatment and suitable CAR T-cell products, as well as protective strategies for medical staff and patients to avoid infection. The arrival of coronavirus disease 2019 (COVID-19) has impacted negatively on the delivery of chimeric antigen receptor (CAR) T-cell therapy to patients with pediatric B-cell acute lymphoblastic leukemia (ALL) and adult B-cell non-Hodgkin lymphomas (NHL). Clinicians can deal with the current challenges of delivering therapy amid a pandemic.

REPORT COVERAGE:

This research report on the global CAR T Cell therapy market is segmented and sub-segmented based on target antigen, Application, Product, therapies, and Region.

CAR T cell Therapy Market - By Target Antigen:

• CD20
• EGFRV III
• CD19
• HER2
• MESO
• CD22
• BCMA
• GD2
• CD30
• HER1
• CD33

Based on target antigen, segments like CD/19 & CD/22 had the largest share in the global market in 2020 and are expected to continue their dominance throughout the forecast period. Recently, several companies got their antigens approved. It also increases the T-cell therapy market. However, B-cell maturation antigens are anticipated to fastest growth due to their distinctive antigens such as MUC16, ROR1, and L1CAM.

CAR T cell Therapy Market - By Application:

• Multiple Myeloma
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Follicular Lymphoma
• Diffuse large B-cell lymphoma
• Acute Lymphoblastic Leukemia

Based on Application, the Multiple Myeloma sector is leading with the highest shares of the market from the past decade. It is also estimated to continue the same growth in the coming years. The multiple myeloma segment has grown in the T cell therapy market. In addition, the new acute lymphocytic leukemia segment is expected to grow in the coming decades. The Diffuse large B-cell lymphoma (DLBCL) segment is another lucrative segment that is next to occupying the second-best majority shares in the market.

CAR T cell Therapy Market - By Product:

• Allogeneic
• Autologous

Based on the product, the autologous segment is anticipated to lead the CAR T Cell therapy market, which owes to several potential competitors, high costs associated with the market, and a considerable number of key players in the forthcoming years.

CAR T cell Therapy Market Analysis - By Therapies:

• Axicabtagene ciloleucel (Yescarta)
• Tisagenlecleucel (Kymriah)

Based on the therapies, the Tisagenlecleucel (Kymriah) segment is expected to account for the largest share in the CAR T cell therapy market. It is due to the increasing occurrence rate of lymphoblastic leukemia and the early accessibility of products that assist in segment growth over the analysis period.

Axicabtagene ciloleucel (Yescarta) is expected to have considerable growth in the market over the analysis period due to the developing healthcare infrastructure and growing discretionary expenses.

CAR T cell Therapy Market – By End User:

• Cancer Research Centers
• Hospitals
• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations

Based on the end-user analysis, the biotechnology and pharmaceutical companies segment witnessed a significant market share over the review period. Due to advanced research carried out at the companies, the segment is leading with the highest shares.

CAR T cell Therapy Market Analysis – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Regionally, North America leads the global market. Because of the quick adoption of advanced technologies and the rise in Cancer, patients are fueling the market demand in this region. In addition, the North American region is continuously growing in the CAR T cell market owing to academic institutions, government authority, and several manufacturing industries. Also, the United States is the highest market in adopting CAR T cell therapy.

The global CAR T cell therapy market, segmented by area, examines growth opportunities and recent developments in Europe, the United States, China, and the Rest of the World. Because of the rapid development and launch of innovative therapies by top industry players to treat Cancer and the large patient pool suffering from Cancer, the United States would dominate the market over the forecast period. The United States, led by Europe, is the leading contributor to global CAR-T cell therapy industry remuneration. Continuous R & R&D, continuing regulatory approvals for new treatments, and developing cancer awareness programs by major players are all accelerating the industry forward in the United States. Swedish Cancer Institute is pleased to give qualifying patients Chimeric Antigen Receptor (CAR)-T cell therapy, one of the most recent immunotherapy types that have resulted in widespread patient remission since its approval in 2017. Since CAR-T cell therapy was only recently approved in April 2017, insurance companies still plan policies for FDA-approved therapies, including CAR-T cell therapy.

Followed by North America, Asia Pacific holds the highest market share with the increased research process on blood cancer treatment. In addition, Asia-pacific is a growing market due to China and India; it has several manufacturing industries and many cancer patients from that Region. 

Europe is the fastest-growing region in the CAR T cell market due to the European medicine agency's recent approvals of Kymriah and Yescarta; it will grow in the CAR T cell market.

KEY MARKET PARTICIPANTS:

Companies playing a leading role in the global CAR T cell therapy market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.

RECENT MARKET DEVELOPMENTS:

• In Dec 2019, the Swiss government approved CAR T cell therapies insurance from Gilead Sciences and Novartis. The Novartis includes Kymriah and Gilead Yescarta therapies system for cancer treatment. The contract between hospitals and health insurers will approve in 2020. 
• In May 2020, Wuxi Advanced Therapies were a development and manufacturing industry that provides end-to-end contracts for innovative therapies. It wants to expand its facility into CAR-T Cell therapy to help gene therapy development and production units. 
• The new product UCART19 is developed to treat CD/19 disease. In addition, Pfizer has partnered with allogeneic to enhance growth and business in allogeneic CAR T cell therapies. 
• In 2018, the Ziopharm Company partnered with Intrexon to advance and develop CAR T cell cancer therapy treatment for substantial tumor disease.